All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43926710" target="_blank" >RIV/00064173:_____/24:43926710 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11120/24:43926710 RIV/00216208:11130/24:10477952 RIV/00064203:_____/24:10477952

  • Result on the web

    <a href="https://doi.org/10.1111/jdv.19916" target="_blank" >https://doi.org/10.1111/jdv.19916</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1111/jdv.19916" target="_blank" >10.1111/jdv.19916</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Risk of squamous cell carcinoma in patients with hidradenitis suppurativa treated with anti-TNF-alpha-Results from a 12-year multicentric observational prospective study

  • Original language description

    Our objective was to investigate the potential link between TNF-alpha inhibitors and the development of cSCC in HS lesions.We prospectively collected data of 299 patients from 18 hospitals in the Czech Republic between January 2011 and March 2023 with moderate to severe HS, treated with adalimumab. Data collection was carried out through the nationwide BIOREP registry, a database that includes patients treated with biologic agents for skin conditions. All patients provided written informed consent. The study included HS patients of any age who received at least one dose of adalimumab (40 mg weekly). Minimal and maximal time of follow-up ranged between 6 and 159 months.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Journal of the European Academy of Dermatology and Venereology

  • ISSN

    0926-9959

  • e-ISSN

    1468-3083

  • Volume of the periodical

    38

  • Issue of the periodical within the volume

    9

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    3

  • Pages from-to

    "e807"-"e809"

  • UT code for WoS article

    001177663300001

  • EID of the result in the Scopus database

    2-s2.0-85186574119